var data={"title":"Glycerol phenylbutyrate: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Glycerol phenylbutyrate: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/538530?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=glycerol-phenylbutyrate-drug-information\" class=\"drug drug_general\">see &quot;Glycerol phenylbutyrate: Drug information&quot;</a> and <a href=\"topic.htm?path=glycerol-phenylbutyrate-patient-drug-information\" class=\"drug drug_patient\">see &quot;Glycerol phenylbutyrate: Patient drug information \t&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20113174\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Ravicti</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49483807\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Ravicti</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F22152386\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Urea Cycle Disorder (UCD) Treatment Agent</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F22152392\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=glycerol-phenylbutyrate-drug-information\" class=\"drug drug_general\">see &quot;Glycerol phenylbutyrate: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric: <b>Urea cycle disorders:</b> <b>Note: </b>Glycerol phenylbutyrate must be used with dietary protein restriction and, in some cases, dietary supplements (eg, essential amino acids, arginine, citrulline, protein-free calorie supplements).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Phenylbutyrate-na&iuml;ve patients:</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">BSA-directed dosing: <b>Note:</b> In patients with some residual enzyme activity and not adequately controlled with protein restriction, the initial dose should be 4.5 <b>mL</b>/m<sup>2</sup>/day (5 g/m<sup>2</sup>/day). Dosing presented as <b>mL</b>. 1 <b>mL</b>=1.1 grams of glycerol phenylbutyrate=1.02 grams of phenylbutyrate.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Infants &ge;2 months and Children &lt;2 years: Oral: Initial: 4.5 to 11.2 <b>mL</b>/m<sup>2</sup>/day (5 to 12.4 g/m<sup>2</sup>/day) in equally divided doses with food/formula 3 or more times daily; round doses up to the nearest 0.1 mL</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Children &ge;2 years and Adolescents: Oral: Initial: 4.5 to 11.2 <b>mL</b>/m<sup>2</sup>/day (5 to 12.4 g/m<sup>2</sup>/day) in equally divided doses with food 3 times daily; round doses up to the nearest 0.5 mL; maximum daily dose: 17.5 <b>mL</b>/day (19 g/day)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Protein intake directed dosing: Infants &ge;2 months, Children, and Adolescents: Oral: Initial: 0.6 <b>mL</b> for every 1 g dietary protein ingested in a 24-hour period; maximum daily dose: 17.5 <b>mL</b>/day (19 g/day); administer in equally divided doses with food; round up to the nearest 0.1 mL (infants &ge;2 months and children &lt;2 years) or 0.5 mL (children &ge;2 years and adolescents)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Patients switching from sodium phenylbutyrate to glycerol phenylbutyrate:</i> Infants &ge;2 months, Children, and Adolescents: Oral: <b>Note: </b>Patients should receive the same amount of phenylbutyric acid from the sodium phenylbutyrate dose. Calculate the dosage of glycerol phenylbutyrate (<b>mL</b>) using the following equation:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Previously taking tablets: Total daily dosage of glycerol phenylbutyrate (<b>mL</b>) = total daily dosage of sodium phenylbutyrate tablets (<b>g</b>) x 0.86</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Previously taking powder: Total daily dosage of glycerol phenylbutyrate (<b>mL</b>) = total daily dosage of sodium phenylbutyrate powder (<b>g</b>) x 0.81</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>Note: </b>Doses should be given in equally divided doses and doses rounded up for infants &ge;2 months and children &lt;2 years to the nearest 0.1 mL and for children &ge;2 years and adolescents to the nearest 0.5 mL.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Dosing adjustment:</i> If symptoms of vomiting, nausea, headache, somnolence, confusion, or sleepiness are present in the absence of high ammonia or other intercurrent illnesses, reduce the dose.</p>\n    <p style=\"text-indent:0em;margin-left:4em;\">\n      <b>Plasma ammonia:</b> When ammonia concentrations are elevated, adjust dose to produce a fasting plasma ammonia concentration to achieve the following goals:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Infants &ge;2 months and Children &lt;6 years: First ammonia concentration of the morning: Below the upper limit of normal. <b>Note:</b> First morning ammonia concentration preferred as this group is harder to obtain a fasting concentration in due to frequent feedings.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Children &ge;6 years and Adolescents: Fasting ammonia concentration: Less than half the upper limit of normal.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>Urinary phenylacetylglutamine (U-PAGN):</b> If U-PAGN excretion is insufficient to cover daily dietary protein intake (1 g U-PAGN excreted covers waste nitrogen from 1.4 g dietary protein) <b>and</b> fasting ammonia is greater than half the upper limit of normal, increase the glycerol phenylbutyrate dose (taking into consideration dietary protein, glycerol phenylbutyrate dose/g of dietary protein, maximum daily dose, and concomitant medications).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>Plasma phenylacetate (PAA) and Phenylacetylglutamine:</b> No specific dosage adjustment recommendations provided; however, if available, the PAA:PAGN ratio may be helpful in guiding dosage decisions. In patients with a high PAA:PAGN ratio, a further increase in glycerol phenylbutyrate dose may not be beneficial as PAGN formation may not increase (even if PAA concentrations are increased) due to saturation of the conjugation reaction.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Adult: Urea cycle disorders:</b> Oral: <b>Note:</b> Doses should be administered in 3 equally divided doses and rounded up to the nearest 0.5 mL; maximum dose: 17.5 mL/day (19 g/day).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Phenylbutyrate-na&iuml;ve patients:</i> 4.5 to 11.2 mL/m<sup>2</sup> (5 to 12.4 g/m<sup>2</sup>) daily; <b>Note:</b> In patients with some residual enzyme activity and not adequately controlled with protein restriction, the initial dose should be 4.5 mL/m<sup>2</sup> (5 g/m<sup>2</sup>) daily.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Patients switching from sodium phenylbutyrate to glycerol phenylbutyrate:</i> Patients should receive the same amount of phenylbutyric acid from the sodium phenylbutyrate dose. Calculate the dosage of glycerol phenylbutyrate (<b>mL</b>) using the following equation:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Total daily dosage of glycerol phenylbutyrate (<b>mL</b>) = total daily dosage of sodium phenylbutyrate tablets (<b>g</b>) x 0.86.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Total daily dosage of glycerol phenylbutyrate (<b>mL</b>) = total daily dosage of sodium phenylbutyrate powder (<b>g</b>) x 0.81.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Dosing adjustment:</i> If symptoms of vomiting, nausea, headache, somnolence, confusion, or sleepiness are present in the absence of high ammonia or other intercurrent illnesses, reduce the dose.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <b>Plasma ammonia:</b> Adjust dose to produce a fasting plasma ammonia level that is less than half the upper limit of normal according to age.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <b>Urinary phenylacetylglutamine (U-PAGN):</b> If U-PAGN excretion is insufficient to cover daily dietary protein intake (1 g U-PAGN excreted covers waste nitrogen from 1.4 g dietary protein) <b>and</b> fasting ammonia is greater than half the upper limit of normal, increase the glycerol phenylbutyrate dose (taking into consideration dietary protein, glycerol phenylbutyrate dose/g of dietary protein, maximum daily dose, and concomitant medications).</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <b>Plasma phenylacetate (PAA):</b> No specific dosage adjustment recommendations provided; however, PAA concentrations and determination of the PAA:PAGN ratio may be helpful in guiding dosage decisions. Clinicians should note that in patients with a high PAA:PAGN ratio, an increase in dose may not be beneficial as PAGN formation may not increase due to saturation of the conjugation reaction.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Dosing adjustment in renal impairment:</b> There are no dosage adjustments provided in the manufacturer&rsquo;s labeling (has not been studied); use with caution.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Dosing adjustment in hepatic impairment:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Mild impairment (Child-Pugh class A): There are no dosage adjustments provided in the manufacturer&rsquo;s labeling; use with caution.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Moderate or severe impairment (Child-Pugh class B or C): There are no dosage adjustments provided in the manufacturer&rsquo;s labeling; initiate dose at the low end of the dosing range; use with caution.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F51112301\" class=\"block dorp drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment (Pediatric)</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer&rsquo;s labeling (has not been studied); use with caution.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F51112302\" class=\"block dohp drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment (Pediatric)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mild impairment (Child-Pugh class A): There are no dosage adjustments provided in the manufacturer&rsquo;s labeling; use with caution.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Moderate or severe impairment (Child-Pugh class B or C): There are no dosage adjustments provided in the manufacturer&rsquo;s labeling; initiate dose at the low end of the dosing range; use with caution.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F17970609\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span><p>(For additional information <a href=\"topic.htm?path=glycerol-phenylbutyrate-drug-information\" class=\"drug drug_general\">see &quot;Glycerol phenylbutyrate: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Urea cycle disorders:</b> Oral: <b>Note:</b> Doses should be administered in 3 equally divided doses and rounded up to the nearest 0.5 mL; maximum dose: 17.5 mL/day (19 g/day).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Phenylbutyrate-na&iuml;ve patients:</i> 4.5 to 11.2 mL/m<sup>2</sup> (5 to 12.4 g/m<sup>2</sup>) daily; <b>Note:</b> In patients with some residual enzyme activity and not adequately controlled with protein restriction, the initial dose should be 4.5 mL/m<sup>2</sup> (5 g/m<sup>2</sup>) daily.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Patients switching from sodium phenylbutyrate to glycerol phenylbutyrate:</i> Patients should receive the same amount of phenylbutyric acid from the sodium phenylbutyrate dose. Calculate the dosage of glycerol phenylbutyrate (<b>mL</b>) using the following equation:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Total daily dosage of glycerol phenylbutyrate (<b>mL</b>) = total daily dosage of sodium phenylbutyrate tablets (<b>g</b>) x 0.86.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Total daily dosage of glycerol phenylbutyrate (<b>mL</b>) = total daily dosage of sodium phenylbutyrate powder (<b>g</b>) x 0.81.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Dosing adjustment:</i>&#65279; <i>&#65279;</i>If symptoms of vomiting, nausea, headache, somnolence, confusion, or sleepiness are present in the absence of high ammonia or other intercurrent illnesses, reduce the dose.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Plasma ammonia:</b> Adjust dose to produce a fasting plasma ammonia level that is less than half the upper limit of normal according to age.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Urinary phenylacetylglutamine (U-PAGN):</b> If U-PAGN excretion is insufficient to cover daily dietary protein intake (1 g U-PAGN excreted covers waste nitrogen from 1.4 g dietary protein) <b>and</b> fasting ammonia is greater than half the upper limit of normal, increase the glycerol phenylbutyrate dose (taking into consideration dietary protein, glycerol phenylbutyrate dose/g of dietary protein, maximum daily dose, and concomitant medications).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Plasma phenylacetate (PAA):</b> No specific dosage adjustment recommendations provided; however, PAA concentrations and determination of the PAA:PAGN ratio may be helpful in guiding dosage decisions. Clinicians should note that in patients with a high PAA:PAGN ratio, an increase in dose may not be beneficial as PAGN formation may not increase due to saturation of the conjugation reaction.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50990180\" class=\"block dora drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment (Adult)</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer&rsquo;s labeling (has not been studied); use with caution.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50987545\" class=\"block doha drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment (Adult)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mild impairment (Child-Pugh class A): There are no dosage adjustments provided in the manufacturer&rsquo;s labeling; use with caution.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Moderate or severe impairment (Child-Pugh class B or C): There are no dosage adjustments provided in the manufacturer&rsquo;s labeling; initiate dose at the low end of the dosing range; use with caution.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F17983053\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Liquid, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Ravicti: 1.1 g/mL (25 mL)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F17970308\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F22904778\" class=\"block accres drugH1Div\"><span class=\"drugH1\">Prescribing and Access Restrictions</span>\n    <p style=\"text-indent:0em;margin-left:0em;display:inline\">Ravicti is only available via select specialty pharmacies. Contact Hyperion UCD Support Services (855-823-7878 or http://www.ucdsupport.com/) for additional information.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16132309\" class=\"block meg drugH1Div\"><span class=\"drugH1\">Medication Guide and/or Vaccine Information Statement (VIS)</span>\n    <p style=\"text-indent:0em;display:inline\">An FDA-approved patient medication guide, which is available with the product information and at <a target=\"_blank\" href=\"https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/203284s005lbl.pdf#page=1&amp;token=NyQFJpN9rZqLV6wXJ9VlJGCeHQbpf9ek055FhbPuNe7hfksJZBePAaEmMR3sBukyPpxrzhUfyfisu3YOVuLhpfH78ET/U8sohY1sDqhCZZlAL6E6L3QCH94nd+km6yWF&amp;TOPIC_ID=114385\" target=\"_blank\">https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/203284s005lbl.pdf#page=1</a>, must be dispensed with this medication.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F22152393\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Oral:</b> Administer with food or formula. Administer directly into mouth using oral syringe or dosing cup. It is recommended that all patients who can swallow take glycerol phenylbutyrate orally, even if a nasogastric and/or gastrostomy tube is present. If patient cannot swallow, may be administered via nasogastric or gastrostomy tube; use an oral syringe to withdraw the prescribed dosage from bottle; place tip of syringe into tip of nasogastric or gastrostomy tube and administer drug. Flush nasogastric or gastronomy tube with 10 mL of water or formula and allow the flush to drain. Flush tube a second time with 10 mL of water or formula to clear the tube. Patients requiring &lt;1 mL per dose via nasogastric or gastrostomy tube should have ammonia concentrations closely monitored during initiation and dosage adjustments; delivered dose may be less than expected due to adherence to plastic tubing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F17970478\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:0em;display:inline\">Store at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F); excursions permitted to 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F22152387\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Chronic management of urea cycle disorders (UCDs) that cannot be managed by dietary protein restriction and/or amino acid supplementation alone (FDA approved in ages &ge;2 months and adults); <b>Note:</b> <b>NOT </b>indicated for the treatment of acute hyperammonemia in patients with UCDs. The safety and efficacy for the treatment of <i>N</i>-acetylglutamate synthase (NAGS) deficiency has not been established.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F17970469\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Dizziness, fatigue, headache (children and adolescents), peripheral neuropathy, seizure</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Skin rash (children &amp; adolescents)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Hyperammonemia</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Abdominal pain, decreased appetite, diarrhea, dyspepsia, flatulence, nausea (less common in adults), upper abdominal pain (children &amp; adolescents), vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Tremor</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rare but important or life-threatening: Body odor (including from hair, skin, urine), burning sensation of mouth, dysgeusia, gag reflex, retching</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F17970418\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity to glycerol phenylbutyrate or any component of the formulation; infants &lt;2 months of age</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Canadian labeling:</i> Additional contraindications (not in US labeling): Breastfeeding.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F17970419\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Neurotoxicity: Signs and symptoms of neurotoxicity may occur due to the presence of phenylacetate (PAA; the active metabolite of phenylbutyrate); reduce dose if symptoms are present (eg, confusion, headache, nausea, sleepiness, somnolence, or vomiting) without increased ammonia levels or other illnesses.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Altered absorption: Use with caution in patients with pancreatic insufficiency or intestinal malabsorption; absorption of glycerol phenylbutyrate may be reduced; monitor ammonia levels closely in these patients.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic impairment: Use caution; dosage adjustment may be necessary in patients with moderate to severe hepatic impairment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Use caution; closely monitor ammonia levels in patients with renal impairment.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>\n        <b>Concurrent drug therapy issues:</b></i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Specific populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pediatric: Infants &lt;2 months of age may have immature pancreatic exocrine function which may impair hydrolysis of glycerol phenylbutyrate and lead to hyperammonemia; use is contraindicated in infants &lt;2 months of age.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: Must be used with dietary protein restriction and, in some cases, dietary supplements (eg, essential amino acids, arginine, citrulline, protein-free calorie supplements). Not indicated for the treatment of acute hyperammonemia; safety and efficacy for the treatment of N-acetylglutamate synthase deficiency has not been established.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50483036\" class=\"block add-pediatric-warn-info drugH1Div\"><span class=\"drugH1\">Warnings: Additional Pediatric Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is recommended that all patients who can swallow take glycerol phenylbutyrate orally, even if a nasogastric and/or gastrostomy tube is present. If patient cannot swallow, glycerol phenylbutyrate may be administered via nasogastric or gastrostomy tube however administration must be followed by a flush of water or formula. Patients requiring &lt;1 mL per dose via nasogastric or gastrostomy should have ammonia concentrations closely monitored during initiation and dosage adjustments; delivered dose may be less than expected due to adherence to plastic tubing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20237843\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Inhibits</b> CYP2C9 (weak); <b>Induces</b> CYP3A4 (weak)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20237841\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=114385&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Benperidol: May diminish the therapeutic effect of Urea Cycle Disorder Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CloZAPine: CYP3A4 Inducers (Weak) may decrease the serum concentration of CloZAPine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Corticosteroids (Systemic): May diminish the therapeutic effect of Urea Cycle Disorder Agents. More specifically, Corticosteroids (Systemic) may increase protein catabolism and plasma ammonia concentrations, thereby increasing the doses of Urea Cycle Disorder Agents needed to maintain these concentrations in the target range.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Haloperidol: May diminish the therapeutic effect of Urea Cycle Disorder Agents. More specifically, Haloperidol may increase plasma ammonia concentrations and thereby increase the doses of Urea Cycle Disorder Agents needed to maintain concentrations in the target range.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">NiMODipine: CYP3A4 Inducers (Weak) may decrease the serum concentration of NiMODipine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Probenecid: May increase serum concentrations of the active metabolite(s) of Urea Cycle Disorder Agents. Specifically, concentrations of phenylacetate and phenylacetylglutamine may be increased.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Valproate Products: May diminish the therapeutic effect of Urea Cycle Disorder Agents. More specifically, Valproate Products may increase plasma ammonia concentrations and thereby increase the doses of Urea Cycle Disorder Agents needed to maintain concentrations in the target range.<i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F17970310\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adverse events have been observed in animal reproduction studies with doses also causing maternal toxicity.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">Health care providers are encouraged to report any prenatal exposure to the manufacturer (www.ucdregistry.com or 1-855-823-2595).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F22152394\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Plasma ammonia, PAA, U-PAGN, PAA:PAGN ratio, hepatic and renal function tests; signs/symptoms of neurotoxicity/hyperammonemia (eg, confusion, headache, nausea, sleepiness, somnolence, vomiting)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F17970479\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Glycerol phenylbutyrate is a prodrug of phenylbutyrate (PBA) which is converted to phenylacetate (PAA) by &beta;-oxidation. Phenylacetate conjugates glutamine to form phenylacetylglutamine (PAGN); PAGN serves as a substitute for urea and clears nitrogenous waste from the body when excreted in the urine.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F17970529\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protein binding: Phenylbutyrate: 81% to 98%; Phenylacetate: 37% to 66%; Phenylacetylglutamine: 7% to 12%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Hepatic and renal: Phenylbutyrate (PBA), a prodrug, is activated by GI lipases. PBA is further metabolized to phenylacetate (PAA) which conjugates with glutamine to form phenylacetylglutamine (PAGN)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Time to peak, plasma: Phenylbutyrate: 2 hours; Phenylacetate: 4 hours; Phenylacetylglutamine: 4 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Time to steady state, plasma: Phenylbutyrate: 8 hours; Phenylacetate: 12 hours; Phenylacetylglutamine: 10 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Urine (primarily as phenylacetylglutamine: Adults ~69%; children ~66%; hepatic impairment 58% to 85%)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F51196142\" class=\"block phksp drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics: Additional Considerations</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hepatic function impairment: PBA and PAA AUC is increased while PAGN AUC is decreased.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gender: Women appear to have higher plasma concentrations of metabolites (C<sub>max</sub> 120% higher) and AUC (108% higher) compared to men at a given dosing level.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20319332\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Liquid</b> (Ravicti Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1.1 g/mL (25 mL): $5,486.40</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49939810\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Ravicti (AT, CZ, DK, EE, GB, HR, IE, LT, LV, PL, PT, SK)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Ravicti oral liquid (glyerol phenylbutyrate) [prescribing information]. Lake Forest, IL: Horizon Pharma USA, Inc; April 2017.</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 114385 Version 7.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F20113174\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F49483807\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F22152386\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F22152392\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment (Pediatric)\" href=\"#F51112301\" class=\"outlineLink\">Dosing: Renal Impairment (Pediatric)</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment (Pediatric)\" href=\"#F51112302\" class=\"outlineLink\">Dosing: Hepatic Impairment (Pediatric)</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F17970609\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment (Adult)\" href=\"#F50990180\" class=\"outlineLink\">Dosing: Renal Impairment (Adult)</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment (Adult)\" href=\"#F50987545\" class=\"outlineLink\">Dosing: Hepatic Impairment (Adult)</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F17983053\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F17970308\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Prescribing and Access Restrictions\" href=\"#F22904778\" class=\"outlineLink\">Prescribing and Access Restrictions</a></li><li class=\"plainItem\"><a sectionName=\"Medication Guide and/or Vaccine Information Statement (VIS)\" href=\"#F16132309\" class=\"outlineLink\">Medication Guide and/or Vaccine Information Statement (VIS)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F22152393\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F17970478\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F22152387\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F17970469\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F17970418\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F17970419\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Warnings: Additional Pediatric Considerations\" href=\"#F50483036\" class=\"outlineLink\">Warnings: Additional Pediatric Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F20237843\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F20237841\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F17970310\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F22152394\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F17970479\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F17970529\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics: Additional Considerations\" href=\"#F51196142\" class=\"outlineLink\">Pharmacodynamics/Kinetics: Additional Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F20319332\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F49939810\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/114385|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=glycerol-phenylbutyrate-drug-information\" class=\"drug drug_general\">Glycerol phenylbutyrate: Drug information</a></li><li><a href=\"topic.htm?path=glycerol-phenylbutyrate-patient-drug-information\" class=\"drug drug_patient\">Glycerol phenylbutyrate: Patient drug information \t</a></li></ul></div></div>","javascript":null}